1.Research progress on mTOR signaling pathway and regulatory T cell nutrition metabolic regulation mechanism.
Chinese Journal of Cellular and Molecular Immunology 2024;40(1):69-73
In the tumor microenvironment, metabolic reprogramming can impact metabolic characteristics of T cells, thus inducing immunosuppression to promote tumor immune escape. The mammalian target of rapamycin (mTOR) signaling pathway plays an important role in regulating diverse functions of various immune cells. This review mainly focuses on the molecular mechanism of mTOR signaling in regulating cellular energy metabolism process, and the activation status of mTOR signaling under different nutritional environments. In addition, it also summarizes the role of the mTOR signaling in regulatory T cell (Tregs) metabolism and function in current studies, and evaluates the potential of mTOR as a clinical immunotherapeutic target and its current application challenges.
Immunosuppression Therapy
;
Metabolic Reprogramming
;
Signal Transduction
;
Sirolimus
;
T-Lymphocytes, Regulatory
;
TOR Serine-Threonine Kinases
;
Humans
2.Progress in targeted inhibition of aerobic glycolysis combined with immunotherapy for renal cell carcinoma.
Kun ZHANG ; Mengyao RU ; Jiayuan WANG ; Jumei ZHAO ; Lan SHEN
Chinese Journal of Cellular and Molecular Immunology 2024;40(1):74-79
Tumor aerobic glycolysis is one of the main features of tumor metabolic reprogramming. This abnormal glycolytic metabolism provides bioenergy and biomaterials for tumor growth and proliferation. It is worth noting that aerobic glycolysis will not only provide biological materials and energy for tumor cells, but also help tumor cells to escape immune surveillance through regulation of immune microenvironment, thereby resisting tumor immunotherapy and promoting tumor progression. Based on the pathogenesis of renal cell carcinoma, this paper describes the characteristics of aerobic glycolysis, the effect of glycolytic metabolism on the immune microenvironment of renal cell carcinoma, the effect of glycolysis inhibitors on the immune microenvironment of renal cell carcinoma, and the prospect of glycolysis inhibitors combined with immune checkpoint inhibitors in the treatment of renal cell carcinoma.
Humans
;
Carcinoma, Renal Cell/therapy*
;
Immunotherapy
;
Glycolysis
;
Metabolic Reprogramming
;
Kidney Neoplasms/therapy*
;
Tumor Microenvironment